Jun 20

ACS-Institutional Research Grant -Phase II Grant Funded to Mitigate Cardiotoxicity of Chemotherapeutics using our Nanocarriers

American Cancer Society - Wikipedia

Excited that our phase-II proposal to the American Cancer Society’s Institutional Research Grant (ACS-IRG) program was funded. This was upon successful phase I completion of our proposal for a novel magnetically driven drug nanocarrier. We propose to use these drug nanocarriers to mitigate cardiotoxicity in the new study. The data generated by the study funded by this should set us up with good preliminary data for NIH and DOD grants.

It is important to note that all this data was majority contributed to by undergraduate researchers.